XPO1 and acute myeloid leukemia: Both preclinical and early phase clinical data suggest that XPO1 inhibitors may elicit additive anti-leukemic activity when combined with established or targeted therapies (Ranganathan et al., 2016; Sweet et al., 2020; Zhang et al., 2018), and synergize with menin inhibition in NPM1c AML (Uckelmann et al., 2022).